Cargando…

EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer

SIMPLE SUMMARY: Lung cancer that is driven by mutations in the epidermal growth factor receptor (EGFR) is currently treated with tyrosine kinase inhibitors (TKIs). Although patients initially respond well to TKI treatment, drug resistance against EGFR-targeted therapy emerges. Attempts to combine im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Selenz, Carolin, Compes, Anik, Nill, Marieke, Borchmann, Sven, Odenthal, Margarete, Florin, Alexandra, Brägelmann, Johannes, Büttner, Reinhard, Meder, Lydia, Ullrich, Roland T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406398/ https://www.ncbi.nlm.nih.gov/pubmed/36010935 http://dx.doi.org/10.3390/cancers14163943

Ejemplares similares

Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors
por: Borchmann, Sven, et al.
Publicado: (2022)

Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous Kras (LSL-G12V) Driven Lung Cancer Mouse Model
por: Meder, Lydia, et al.
Publicado: (2021)

SQSTM1/p62 promotes miR-198 loading into extracellular vesicles and its autophagy-related secretion
por: Yu, Xiaojie, et al.
Publicado: (2022)

EGFR/Ras-induced CCL20 production modulates the tumour microenvironment
por: Hippe, Andreas, et al.
Publicado: (2020)

Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
por: Santaniello, Antonio, et al.
Publicado: (2019)

Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment
por: Kapoor, Simran S., et al.
Publicado: (2021)

Correction to: EGFR/Ras-induced CCL20 production modulates the tumour microenvironment
por: Hippe, Andreas, et al.
Publicado: (2021)

Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification
por: Dekanić, Andrea, et al.
Publicado: (2011)

Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
por: Fassunke, Jana, et al.
Publicado: (2018)

EGFR inhibition in EGFR‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment
por: Shiiya, Akihiko, et al.
Publicado: (2022)

P046: Preclinical evaluation of novel repurposed drug combinations in Hodgkin lymphoma
por: Lohmann, Mia, et al.
Publicado: (2022)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
por: Yang, Wang, et al.
Publicado: (2020)

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
por: Kirchner, M., et al.
Publicado: (2021)

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas
por: Magkou, Christina, et al.
Publicado: (2008)

Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer
por: Schaufler, Diana, et al.
Publicado: (2021)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors
por: Pedicini, Piernicola, et al.
Publicado: (2012)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

IgA EGFR antibodies mediate tumour killing in vivo
por: Boross, Peter, et al.
Publicado: (2013)

Egfr Amplification Specific Gene Expression in Phyllodes Tumours of the Breast
por: Agelopoulos, Konstantin, et al.
Publicado: (2007)

The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment
por: Huang, Peixin, et al.
Publicado: (2014)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
por: Lemmon, Christopher, et al.
Publicado: (2020)

Identification of a Gene Signature Closely Related to Immunosuppressive Tumour Microenvironment Predicting Prognosis of Patients in EGFR Mutant Lung Adenocarcinoma
por: Li, Jia, et al.
Publicado: (2021)

Correction: modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors
por: Pedicini, Piernicola, et al.
Publicado: (2012)

Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours
por: Yue-Yun, Chen, et al.
Publicado: (2019)

Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations
por: Macheleidt, Iris F., et al.
Publicado: (2018)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment
por: Lauriola, Mattia, et al.
Publicado: (2014)

Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein
por: Laviolette, Laura A., et al.
Publicado: (2017)

EGFR-dependent aerotaxis is a common trait of breast tumour cells
por: Mikaelian, Ivan, et al.
Publicado: (2022)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Pericentromeric Satellite III transcripts induce etoposide resistance
por: Kanne, Julian, et al.
Publicado: (2021)

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
por: Roeper, Julia, et al.
Publicado: (2020)

Tumour-Associated Transcripts and EGFR Deletion Variants in Colorectal Cancer in Primary Tumour, Metastases and Circulating Tumour Cells
por: Lankiewicz, Silke, et al.
Publicado: (2008)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
por: Panousis, C, et al.
Publicado: (2005)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR
por: Wang, Anbang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tljhlajcob1t5kg2omqi89t914